With Rare Resolve.
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for rare diseases of the immune system. Its lead asset, mavorixafor (XOLREMDI®), has received U.S. FDA approval for its first indication in WHIM syndrome, with ongoing Phase 3 trials in chronic neutropenic disorders. X4 is headquartered in Boston and trades on Nasdaq under XFOR.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountOct 2025
Aug 2025
Aug 2025
May 2024
Mar 2021
Mar 2018
Dec 2015
Jan 2015
Create a free account to see which investors have funded this company.
Create Free Account
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
